Glipizide and Nucynta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Glipizide (glipizide) and Nucynta (tapentadol hydrochloride). Common drug interactions include cerebrovascular accident among females and dyspnoea among males.

The phase IV clinical study analyzes what interactions people have when they take Glipizide and Nucynta. It is created by eHealthMe based on reports of 47 people who take the same drugs from the FDA, and is updated regularly.

What is Glipizide?

Glipizide has active ingredients of glipizide. It is often used in diabetes. eHealthMe is studying from 64,852 Glipizide users. Check the latest studies of Glipizide.

What is Nucynta?

Nucynta has active ingredients of tapentadol hydrochloride. It is often used in pain. eHealthMe is studying from 31,818 Nucynta users. Check the latest studies of Nucynta.



On Jul, 08, 2026

47 people who take Glipizide and Nucynta together, and have interactions are studied.

Glipizide and Nucynta drug interactions.

What are the common drug interactions of Glipizide and Nucynta, by gender? *:

female:

  1. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  2. Chronic kidney disease
  3. Nausea (feeling of having an urge to vomit)
  4. Chronic sinusitis (long lasting inflammation of the paranasal sinuses)
  5. Haemorrhage (bleeding)
  6. Renal failure (kidney dysfunction)
  7. Urinary tract infection
  8. Asthenia (weakness)
  9. Cardiac failure congestive
  10. Cystitis (inflammation of the wall of the bladder)

male:

  1. Dyspnoea (difficult or laboured respiration)
  2. Asthenopia (eyestrain-tiredness of the eyes caused by prolonged close work by a person with an uncorrected vision problem)
  3. Abdominal pain
  4. Alopecia (absence of hair from areas of the body)
  5. Anaemia (lack of blood)
  6. Aphonia (inability to produce voice)
  7. Arthralgia (joint pain)
  8. Asthenia (weakness)
  9. Chest discomfort
  10. Chest pain

What are the common drug interactions of Glipizide and Nucynta, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Renal failure (kidney dysfunction)
  2. Blood pressure increased
  3. Cardiac flutter (abnormal heart rhythm)
  4. Chronic kidney disease
  5. Contusion (a type of hematoma of tissue in which capillaries)
  6. Dizziness
  7. Dyspnoea (difficult or laboured respiration)
  8. Eye pain
  9. Fall
  10. Joint swelling

50-59:

  1. Asthenopia (eyestrain-tiredness of the eyes caused by prolonged close work by a person with an uncorrected vision problem)
  2. Dyspnoea (difficult or laboured respiration)
  3. Feeling drunk
  4. Gait disturbance
  5. Cyst (a closed sac)

60+:

  1. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  2. Chronic kidney disease
  3. Dyspnoea (difficult or laboured respiration)
  4. Fatigue (feeling of tiredness)
  5. Lower gastrointestinal haemorrhage (bleeding in the large intestine, rectum, or anus is called lower gi bleeding)
  6. Renal injury (kidney injury)
  7. Urinary tract infection
  8. Urosepsis (secondary infection that occurs when a urinary tract infection spreads to the bloodstream)
  9. Abdominal pain
  10. Alopecia (absence of hair from areas of the body)

What are the existing conditions these people have? *

  1. Back Pain: 11 people, 23.40%
  2. High Blood Cholesterol: 10 people, 21.28%
  3. Herniated Nucleus Pulposus (Slipped Disk): 9 people, 19.15%
  4. High Blood Pressure: 9 people, 19.15%
  5. Post Herpetic Neuralgia (neuralgia caused by the varicella zoster virus): 9 people, 19.15%
  6. Depression: 7 people, 14.89%
  7. Type 2 Diabetes: 7 people, 14.89%
  8. Neuralgia (pain in one or more nerves): 5 people, 10.64%
  9. Stress And Anxiety: 5 people, 10.64%
  10. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 10.64%

* Approximation only. Some reports may have incomplete information.

Do you take Glipizide and Nucynta?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Glipizide and Nucynta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Glipizide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Nucynta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Glipizide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Nucynta and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on glipizide and tapentadol hydrochloride (the active ingredients of Glipizide and Nucynta, respectively), and Glipizide and Nucynta (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: